p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 38-47

  Kelly, Julie A ^a   Scott Lucia, M ^a   Lambert, James R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

DNA damage; Hypoxia; p53; PDF MIC 1 NAG 1; Prostate cancer

Indexed keywords

COBALT CHLORIDE; DOXORUBICIN; GROWTH DIFFERENTIATION FACTOR 15; MESSENGER RNA; PROSTATE DERIVED FACTOR; PROTEIN; PROTEIN NAG 1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DENSITY; CELL HYPOXIA; CELL STRAIN LNCAP; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; RNA STABILITY;

CELL COUNT; CELL HYPOXIA; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA STABILITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61849084730     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.013     Document Type: Article

References (49)

1. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 59 (2001) 901-908
2. Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., Zhang H.P., Donnellan M., Mahler S., Pryor K., Walsh B.J., Nicholson R.C., Fairlie W.D., Por S.B., Robbins J.M., and Breit S.N. MIC-1, A novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA 94 (1997) 11514-11519
3. Bottner M., Laaff M., Schechinger B., Rappold G., Unsicker K., and Suter-Crazzolara C. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 237 (1999) 105-111
4. Tan M., Wang Y., Guan K., and Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc. Natl. Acad. Sci. USA 97 (2000) 109-114
5. Hromas R., Hufford M., Sutton J., Xu D., Li Y., and Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim. Biophys. Acta 1354 (1997) 40-44
6. Lambert J.R., Kelly J.A., Shim M., Huffer W.E., Nordeen S.K., Baek S.J., Eling T.E., and Lucia M.S. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J. Cell Physiol. 208 (2006) 566-574
7. Nazarova N., Qiao S., Golovko O., Lou Y.R., and Tuohimaa P. Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth. Int. J. Cancer 112 (2004) 951-958
8. Baek S.J., Kim J.S., Jackson F.R., Eling T.E., McEntee M.F., and Lee S.H. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 25 (2004) 2425-2432
9. Baek S.J., Wilson L.C., and Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23 (2002) 425-434
10. Bottone Jr. F.G., Baek S.J., Nixon J.B., and Eling T.E. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J. Nutr. 132 (2002) 773-778
11. Wilson L.C., Baek S.J., Call A., and Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int. J. Cancer 105 (2003) 747-753
12. Yamaguchi K., Liggett J.L., Kim N.C., and Baek S.J. Anti-proliferative effect of horehound leaf and wild cherry bark extracts on human colorectal cancer cells. Oncol. Rep. 15 (2006) 275-281
13. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., and Baek S.J. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun. 328 (2005) 63-69
14. Baek S.J., Wilson L.C., Hsi L.C., and Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278 (2003) 5845-5853
15. Chintharlapalli S., Papineni S., Baek S.J., Liu S., and Safe S. 1, 1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol. Pharmacol. 68 (2005) 1782-1792
16. Yamaguchi K., Lee S.H., Eling T.E., and Baek S.J. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol. Cancer Ther. 5 (2006) 1352-1361
17. Appierto V., Villani M.G., Cavadini E., Gariboldi M., De C.L., Pierotti M.A., Lambert J.R., Reid J., Tiberio P., Colombo N., and Formelli F. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells. Oncogene 26 (2007) 3952-3962
18. Soto-Cerrato V., Vinals F., Lambert J.R., Kelly J.A., and Perez-Tomas R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol. Cancer Ther. 6 (2007) 362-369
19. Monks A., Harris E., Hose C., Connelly J., and Sausville E.A. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol. Pharmacol. 63 (2003) 766-772
20. Newman D., Sakaue M., Koo J.S., Kim K.S., Baek S.J., Eling T., and Jetten A.M. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol. Pharmacol. 63 (2003) 557-564
21. Lee S.H., Yamaguchi K., Kim J.S., Eling T.E., Safe S., Park Y., and Baek S.J. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27 (2006) 972-981
22. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., Mishina Y., Martin D.W., Shoieb A., McEntee M.F., and Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131 (2006) 1553-1560
23. Paralkar V.M., Vail A.L., Grasser W.A., Brown T.A., Xu H., Vukicevic S., Ke H.Z., Qi H., Owen T.A., and Thompson D.D. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J. Biol. Chem. 273 (1998) 13760-13767
24. Shim M., and Eling T.E. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J. Biol. Chem. 280 (2005) 18636-18642
25. Koopmann J., Buckhaults P., Brown D.A., Zahurak M.L., Sato N., Fukushima N., Sokoll L.J., Chan D.W., Yeo C.J., Hruban R.H., Breit S.N., Kinzler K.W., Vogelstein B., and Goggins M. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10 (2004) 2386-2392
26. Koopmann J., Rosenzweig C.N., Zhang Z., Canto M.I., Brown D.A., Hunter M., Yeo C., Chan D.W., Breit S.N., and Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin. Cancer Res. 12 (2006) 442-446
27. Brown D.A., Ward R.L., Buckhaults P., Liu T., Romans K.E., Hawkins N.J., Bauskin A.R., Kinzler K.W., Vogelstein B., and Breit S.N. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin. Cancer Res. 9 (2003) 2642-2650
28. Selander K.S., Brown D.A., Sequeiros G.B., Hunter M., Desmond R., Parpala T., Risteli J., Breit S.N., and Jukkola-Vuorinen A. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 532-537
29. Welsh J.B., Sapinoso L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., Frierson Jr. H.F., and Hampton G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61 (2001) 5974-5978
30. Karan D., Chen S.J., Johansson S.L., Singh A.P., Paralkar V.M., Lin M.F., and Batra S.K. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem. Biophys. Res. Commun. 305 (2003) 598-604
31. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., Austin R.C., and Klamut H.J. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J. Biol. Chem. 275 (2000) 20127-20135
32. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67 (2005) 356-364
33. Yamaguchi K., Lee S.H., Eling T.E., and Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J. Biol. Chem. 279 (2004) 49617-49623
34. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
35. Lavin M.F., and Gueven N. The complexity of p53 stabilization and activation. Cell Death. Differ. 13 (2006) 941-950
36. Albertoni M., Shaw P.H., Nozaki M., Godard S., Tenan M., Hamou M.F., Fairlie D.W., Breit S.N., Paralkar V.M., De T.N., Van Meir E.G., and Hegi M.E. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 21 (2002) 4212-4219
37. Zimmers T.A., Jin X., Hsiao E.C., McGrath S.A., Esquela A.F., and Koniaris L.G. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23 (2005) 543-548
38. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
39. Bar J., Cohen-Noyman E., Geiger B., and Oren M. Attenuation of the p53 response to DNA damage by high cell density. Oncogene 23 (2004) 2128-2137
40. Meerson A., Milyavsky M., and Rotter V. P53 mediates density-dependent growth arrest. FEBS Lett. 559 (2004) 152-158
41. Koumenis C., Alarcon R., Hammond E., Sutphin P., Hoffman W., Murphy M., Derr J., Taya Y., Lowe S.W., Kastan M., and Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 21 (2001) 1297-1310
42. Martinez J.M., Sali T., Okazaki R., Anna C., Hollingshead M., Hose C., Monks A., Walker N.J., Baek S.J., and Eling T.E. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J. Pharmacol. Exp. Ther. 318 (2006) 899-906
43. Michael D., and Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12 (2002) 53-59
44. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
45. Yang H., Filipovic Z., Brown D., Breit S.N., and Vassilev L.T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2 (2003) 1023-1029
46. Rasiah K.K., Kench J.G., Gardiner-Garden M., Biankin A.V., Golovsky D., Brenner P.C., Kooner R., O'neill G.F., Turner J.J., Delprado W., Lee C.S., Brown D.A., Breit S.N., Grygiel J.J., Horvath L.G., Stricker P.D., Sutherland R.L., and Henshall S.M. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 711-716
47. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 8621-8623
48. Iida T., Mine S., Fujimoto H., Suzuki K., Minami Y., and Tanaka Y. Hypoxia-inducible factor-1alpha induces cell cycle arrest of endothelial cells. Genes Cells 7 (2002) 143-149
49. Li C., Issa R., Kumar P., Hampson I.N., Lopez-Novoa J.M., Bernabeu C., and Kumar S. CD105 prevents apoptosis in hypoxic endothelial cells. J. Cell Sci. 116 (2003) 2677-2685